Omni Partners’s Humacyte Inc Warrant HUMAW Stock Holding History

Omni Partners’s Portfolio HUMAW Stock Details HUMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-589,061	Closed	-$677K	–	259
2020 Q4	$677K	Buy	+589,061	New	+$556K	0.04%	153

Other funds holding HUMAW

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

P. Schoenfeld Asset Management (PSAM) New York $244M AUM 110.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

Omni Partners's HUMAW Position: Q1 2021 in Review

Omni Partners sold out of Humacyte Inc Warrant (HUMAW) in Q1 2021, closing a stake of 589,061 shares — an estimated $677K sold.

Omni Partners first reported a position in HUMAW in Q4 2020 and held it in 1 quarter. The position peaked at $677K in Q4 2020. 13 funds tracked by Wall St. Rank hold HUMAW as of Q1 2021.

Omni Partners reported no remaining Humacyte Inc Warrant position as of Q1 2021 after selling out during the quarter.
Omni Partners sold 589,061 Humacyte Inc Warrant shares in Q1 2021, an estimated $677K.
Omni Partners first reported a position in Humacyte Inc Warrant in Q4 2020 and held it in 1 quarter.
Omni Partners's Humacyte Inc Warrant position peaked at $677K in Q4 2020.
13 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q1 2021.

Based on Omni Partners's 13F filing for Q1 2021, filed 17 May 2021.